Journal article
Making a better antibody: all is not lost
Blood, Vol.115(25), pp.5127-5128
06/24/2010
DOI: 10.1182/blood-2010-03-275206
PMID: 20576817
Abstract
Effective anticancer therapy requires effective targeting of the malignant cells. In this issue of Blood, Beers and colleagues demonstrate that rituximab-induced loss of CD20 from the surface of B cells may explain why rituximab is more effective in some B-cell malignancies, such as follicular lymphoma, than in others like CLL.1 They also provide evidence that anti-CD20 mAb, designated type II anti-CD20 mAb, induce considerably less down-modulation of CD20 than rituximab, and therefore could be more effective therapeutically.
Details
- Title: Subtitle
- Making a better antibody: all is not lost
- Creators
- George J. Weiner - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.115(25), pp.5127-5128
- DOI
- 10.1182/blood-2010-03-275206
- PMID
- 20576817
- NLM abbreviation
- Blood
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 06/24/2010
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984360046702771
Metrics
6 Record Views